Dare Bioscience, Inc. (DARE) stock
DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.43−0.16 (-26.57%)
Close on Nov 17, 2026Market cap $6.56MP/E –Yield –
Dare Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Dare Bioscience's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.70M, down 72.3% year over year. For fiscal 2025 it was $5.52M, down 61.4% from the year before. Over ten years it grew -14.3% a year on average. The highest annual figure on record is $30.62M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.52M | -61.4% |
| FY2024 | Dec 31, 2024 | $14.31M | -33.6% |
| FY2023 | Dec 31, 2023 | $21.54M | -28.3% |
| FY2022 | Dec 31, 2022 | $30.04M | -1.9% |
| FY2021 | Dec 31, 2021 | $30.62M | +47.4% |
| FY2020 | Dec 31, 2020 | $20.77M | +143.0% |
| FY2019 | Dec 31, 2019 | $8.55M | +33.2% |
| FY2018 | Dec 31, 2018 | $6.41M | +551.3% |
| FY2017 | Dec 31, 2017 | $984.75K | +1255.2% |
| FY2016 | Dec 31, 2016 | $72.67K | -99.7% |
| FY2015 | Dec 31, 2015 | $25.95M | +120.4% |
| FY2014 | Dec 31, 2014 | $11.77M | +21.4% |
| FY2013 | Dec 31, 2013 | $9.70M | -38.6% |
| FY2012 | Dec 31, 2012 | $15.81M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $241.97K | -83.1% |
| Q1 FY2026 | Mar 31, 2026 | $660.46K | -71.3% |
| Q4 FY2025 | Dec 31, 2025 | $622.04K | -81.4% |
| Q3 FY2025 | Sep 30, 2025 | $1.18M | -56.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.43M | -71.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.30M | -31.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.34M | -12.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.68M | -59.8% |
| Q2 FY2024 | Jun 30, 2024 | $4.93M | -18.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.35M | -33.2% |
| Q4 FY2023 | Dec 31, 2023 | $3.80M | -70.7% |
| Q3 FY2023 | Sep 30, 2023 | $6.67M | +49.6% |
| Q2 FY2023 | Jun 30, 2023 | $6.04M | -11.1% |
| Q1 FY2023 | Mar 31, 2023 | $5.02M | -13.5% |
| Q4 FY2022 | Dec 31, 2022 | $12.98M | +82.3% |
| Q3 FY2022 | Sep 30, 2022 | $4.46M | -57.2% |
| Q2 FY2022 | Jun 30, 2022 | $6.80M | -7.4% |
| Q1 FY2022 | Mar 31, 2022 | $5.81M | +1.3% |
| Q4 FY2021 | Dec 31, 2021 | $7.12M | +7.2% |
| Q3 FY2021 | Sep 30, 2021 | $10.43M | +68.2% |
| Q2 FY2021 | Jun 30, 2021 | $7.34M | +32.3% |
| Q1 FY2021 | Mar 31, 2021 | $5.73M | +140.7% |
| Q4 FY2020 | Dec 31, 2020 | $6.64M | +179.6% |
| Q3 FY2020 | Sep 30, 2020 | $6.20M | +215.5% |
| Q2 FY2020 | Jun 30, 2020 | $5.55M | +120.8% |
| Q1 FY2020 | Mar 31, 2020 | $2.38M | +40.5% |
| Q4 FY2019 | Dec 31, 2019 | $2.37M | +42.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.97M | +35.9% |
| Q2 FY2019 | Jun 30, 2019 | $2.51M | +13.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.69M | +55.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.66M | +147.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.45M | +415.2% |
| Q2 FY2018 | Jun 30, 2018 | $2.22M | +61914.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.09M | +3808.8% |
| Q4 FY2017 | Dec 31, 2017 | $672.58K | -78.9% |
| Q3 FY2017 | Sep 30, 2017 | $280.79K | -96.0% |
| Q2 FY2017 | Jun 30, 2017 | $3.58K | – |
| Q1 FY2017 | Mar 31, 2017 | $27.80K | – |
| Q4 FY2016 | Dec 31, 2016 | $3.18M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.09M | – |
See a number that looks wrong?